期刊文献+

外泌体及其工程化应用于缺血性脑卒中的研究进展 被引量:1

Research progress on exosomes and their engineering in ischemic stroke
下载PDF
导出
摘要 缺血性脑卒中是一种致残率和死亡率极高的脑血管疾病。目前,尚无有效的治疗方法能够促进缺血性脑卒中后的神经功能恢复。外泌体既可以介导细胞之间的通信,又具有跨越血脑屏障的能力,故在缺血性脑卒中的治疗中受到广泛关注。利用生物工程技术修饰改造外泌体,制备具有脑靶向性和治疗作用的工程化外泌体,应用于缺血性脑卒中的研究与治疗,以期提高脑卒中后神经功能的修复,减少临床致残率和死亡率,提高患者的生存和生活质量。本文从外泌体、外泌体在缺血性脑卒中的作用、工程化外泌体的制备等方面进行综述,并讨论工程化外泌体在治疗缺血性脑卒中的应用前景,以期为后续研究提供参考。 Ischemic stroke is a cerebrovascular disease with high disability rate and mortality.At present,there is no effective treatment to promote the recovery of neurological function after ischemic stroke.Exosomes can not only mediate the communication between cells,but also have the ability to cross the blood-brain barrier,so they have received extensive attention in the treatment of ischemic stroke.Exosomes are modified by bioengineering technologies to prepare engineered exosomes with brain targeting and therapeutic effects,which have been applied in the research and treatment of ischemic stroke,in order to improve the repair of neurological function after stroke,reduce the clinical disability rate and mortality,and improve the survival and quality of life of patients.This article reviews exosomes,the role of exosomes in ischemic stroke,and the preparation of engineered exosomes,and discusses the application prospect of engineered exosomes in the treatment of ischemic stroke,with a view to providing a reference for subsequent research.
作者 杨悦悦 马素娜 陈净 吴松 关梦雅 王晶莹(综述) 任彬彬(审校) YANG Yueyue;MA Suna;CHEN Jing(Henan University of Chinese Medicine,Zhengzhou 450000,China)
出处 《中风与神经疾病杂志》 CAS 2023年第7期667-672,共6页 Journal of Apoplexy and Nervous Diseases
基金 2022年度河南省中医药拔尖人才培养项目专项课题(2022ZYBJ09) 2022年财政专项-中医药传承与创新人才工程(CZ0262-10-02)。
关键词 外泌体 缺血性脑卒中 生物工程技术 工程化外泌体 Exosomes Ischemic stroke Bioengineering technology Engineered exosomes
  • 相关文献

参考文献5

二级参考文献91

  • 1Kooijmans S A A, Vader P, van Dommelen S M, van Solinge W W, Schiffelers R M. Int. J. Nanomed. , 2012, 7: 1525.
  • 2Johnsen K B, Gudbergsson J M, Skov M N, Pilgaard L, Moos T, Duroux M. Biochimica. et. Biophysica. Acta, 2014, 1846: 75.
  • 3Qin J, Xu Q. Acta Pol. Pharm. , 2014, 71: 537.
  • 4Lakhal S, Wood M J. Bioessays, 2011, 33: 737.
  • 5Zocco D, Ferruzzi P, Cappello F, Kuo W P, Fais S. Front. Oncol. , 2014, 4: 2.
  • 6Jang S C, Kim O Y, Yoon C M, Choi D S, Roh T Y, Park J, Nilsson J, Lotvall J, Kim Y K, Gho Y S. ACS Nano, 2013, 7: 7698.
  • 7Chen L, Wang Y, Pan Y, Zhang L, Shen C, Qin G, Ashraf M, Weintraub N, Ma G, Tang Y. Biochem. Biophys. Res. Commun. , 2013, 431: 566.
  • 8Bryniarski K, Ptak W, Jayakumar A, Pullmann K, Caplan M J, Chairoungdua A, Lu J, Adams B D, Sikora E, Nazlmek K, Marquez S, Kleinstein S H, Sangwung P, Iwakiri Y, Delgato E, Redegeld F, Blokhuis B R, Wojcikowski J, Daniel A W, Kormelink T G, Askenase P W. J. Allergy Clin. Immunol. , 2013, 132: 170.
  • 9Yn L, Yang F, Jiang L, Chen Y, Wang K, Xu F, Wei Y, Cao X, Wang J, Cai Z. Eur. J. Immunol. , 2013, 43: 2461.
  • 10Sun D M, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang H G, Mol. Ther. , 2010, 18: 1606.

共引文献50

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部